Aclaris ATI-2138 Phase 2a AD trial meets primary and key secondary endpoints; 60.5% mean EASI improvement at week 12

Aclaris Therapeutics, Inc.

14 patients enrolled; 10 per protocol; no SAEs or discontinuations; well tolerated with mild, transient TRAEs.
Mean EASI improvement 60.5% (77.1% excluding one outlier); 62.5% achieved ≥4-point itch reduction at week 12.
PD data show near-complete ITK target occupancy and downregulation of Th2, Th1/Th17, and fibrosis markers.
Company plans to further develop ATI-2138 in alopecia areata and explore other indications.
Preclinical work ongoing for next-gen ITK inhibitors; new INDs expected starting 2026.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.